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Abstract
Octocrylene or octocrilene is an organic ultraviolet (UV) ﬁlter which absorbs mainly UVB radiation and short UVA wave-
lengths. It is used in various cosmetic products to either provide an appropriate sun protection factor in sunscreen prod-
ucts or to protect cosmetic formulations from UV radiation. There is no discussion that UV ﬁlters are beneﬁcial
ingredients in cosmetics since they protect from skin cancer, but octocrylene has been recently incriminated to poten-
tially induce adverse effects on the endocrine system in addition to having allergic and/or photoallergic potential. How-
ever, the substance has the advantage to work synergistically with other ﬁlters allowing a beneﬁcial broad
photoprotection, e.g. it stabilizes the UVA ﬁlter avobenzone (i.e. butylmethoxydibenzoylmethane). Like all chemicals
used in cosmetics, the safety proﬁle of octocrylene is constantly under assessment by the European Chemical Agency
(ECHA) since it has been registered according to the European regulation Registration, Evaluation, Authorisation and
Restriction of Chemicals. Summaries of safety data of octocrylene are publicly available on the ECHA website. This
review aims to present the main safety data from the ECHA website, as well as those reported in scientiﬁc articles from
peer-reviewed journals. The available data show that octocrylene does not have any endocrine disruption potential. It is
a rare sensitizer, photocontact allergy is more frequent and it is considered consecutive to photosensitization to ketopro-
fen. Based on these results, octocrylene can be considered as safe when used as a UV ﬁlter in cosmetic products at a
concentration up to 10%.
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Introduction
Octocrylene or octocrilene (CAS n. 6197-30-4) is an organic
compound with an aromatic structure which is also known as 2-
ethylhexyl 2-cyano-3,3-diphenyl-2-propenoate; 2-ethylhexyl 2-
cyano-3,3-diphenylacrylate or the 2-ethylhexyl ester of 2-cyano-
3,3-diphenyl acrylic acid.
It is an organic ultraviolet (UV) filter, which absorbs mainly
UVB radiation and short UVA wavelengths.1 Due to its UV radi-
ation absorption properties, it is used in sunscreens with other
UV filters to provide an adequate sun protection factor (SPF). It
is also used to stabilize other UV filters such as avobenzone, a fil-
ter particularly effective against UVA2; this association thus pro-
vides an optimal UV protection. Various cosmetic products
such as facial creams or lip care products contain octocrylene to
either provide an adequate SPF or to protect the cosmetic for-
mulation from UV radiation.3
In Europe, UV filters allowed in cosmetic products are regu-
lated in Annex VI of Cosmetics Regulation (EC) No. 1223/2009.
According to this regulation, octocrylene is authorized as a UV
filter in cosmetic formulations at a maximum concentration of
10.0% as acid form in Europe (Annex VI/10). Of note, octocry-
lene is also authorized as a UV filter in sunscreen products in the
same conditions in the USA.
Octocrylene may cause allergies and/or (photo)allergies and
has been suspected to have an endocrine disrupting activity.
Indeed, in 2013, the Danish Centre on Endocrine Disrupters
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assessed the endocrine disrupting potential of all UV filters used
in Europe, including octocrylene.4 In addition, on 16 May 2019,
the European Commission called for data on a list of 14 ingredi-
ents – including octocrylene – with potential disrupting proper-
ties used in cosmetic products (https://ec.europa.eu/growth/c
ontent/call-data-ingredients-potential-endocrine-disrupting-
properties-used-cosmetic-products_en). The objective of the
present document is therefore to evaluate the safety of octocry-
lene on the basis of the publicly available safety data from scien-
tific literature and safety agencies. It is worth noting that the risk
assessment of a chemical substance performed by European
safety agencies such as the European Chemical Agency (ECHA)
is based on the appraisal of all relevant publicly available infor-
mation on this ingredient, including results from in vitro and
in vivo studies published in peer-reviewed journals and from
unpublished studies carried out by the manufacturers at the
request of safety agencies. Both kinds of results are summarized
below.
Method of data search
Octocrylene has been recently registered at the European level in
Regulation (EC) No. 1907/2006 concerning the Registration,
Evaluation, Authorisation and Restriction of Chemicals. It is
under assessment by the ECHA. Although the assessment has
not been finalized because additional data were requested by the
ECHA from the product manufacturers, summaries of safety
data are available since 2014 and were recently updated with
additional data on ECHA website.5 In addition, published safety
data on octocrylene were updated by searching publications in
peer-reviewed journals available on PubMed at the end of Jan-
uary 2019. The following search terms were used: ‘octocrylene’
OR ‘octocrilene’. No limits for publication dates were set. The
articles were screened by two reviewers based on titles and
abstracts, only those dealing with the safety of octocrylene were
selected. Of note, all articles dealing with environmental effects
of octocrylene were excluded. Finally, a manual search of data
available in grey literature was conducted.
Absorption and bioavailability data
Transdermal/percutaneous absorption
Four studies on the transdermal absorption of octocrylene are
available in the scientific literature,6–9 and an additional study is
available in ECHA summaries of safety data (unpublished study
as cited by ECHA, 20195). All of these studies were performed
in vitro on human skin samples maintained alive. The article of
Potard et al.9 also included an in vivo absorption study of octo-
crylene in the stratum corneum of humans.
The results of these studies showed that 16–24 h after applica-
tion of octocrylene (8–10%) on the surface of skin samples, most
of the octocrylene remained on the surface of the skin as non-
penetrated material (>95%) and detectable amounts of the
applied dose were found in the stratum corneum, and in low
amounts or below the detection limit in other skin layers (epi-
dermis, dermis or receptor medium). None of the authors deter-
mined a percentage of dermal absorption. Hayden’s study
showed that only 0.4% of octocrylene was found in the epider-
mis and approximatively 0.05% in the fluid receptor.7 Therefore,
it can be concluded that transdermal absorption of octocrylene
is very low.
Bioavailability
No specific animal data on octocrylene kinetics are available in
the scientific literature as well as in the grey literature (e.g. data
available on ECHA website). In an oral 90-day toxicity study con-
ducted in rats, octocrylene was shown to be bioavailable in the
gastro-intestinal tract.5 Data in humans available in the scientific
literature contain assessment of exposure to octocrylene and show
that octocrylene was found in human milk after dermal exposure
at very low amounts – i.e. 27.50  22.15 ng/g of lipids.10 Human
metabolism is under investigation by a research team (publication
in preparation as mentioned by Bury et al. 2), who recently identi-
fied three metabolites, 2-cyano-3,3-diphenylacrylic acid (CPAA),
2-ethyl-5-hydroxyhexyl 2-cyano-3,3-diphenyl acrylate (5OH–OC)
and 2-(carboxymethyl)butyl 2-cyano-3,3-diphenyl acrylate (‘dinor
OC carboxylic acid’, DOCCA) in a pilot biomonitoring study in
the urine of 35 volunteers not occupationally exposed to octocry-
lene. Results of this pilot study showed that metabolites of octo-
crylene were primarily found at low concentrations – i.e. 59.0
(38.4–95.5) lg/L for CPAA; 0.663 (0.651–0.805) lg/L for
DOCCA; 0.044 (0.030–0.093) lg/L 5 OH–C – in urine of volun-
teers using sunscreen products. However, those results need to be
confirmed in a larger population.
A study published in May 2019 also assessed the systemic
availability in human of some UV filters including octocry-
lene.11 This randomized clinical trial included 24 healthy partic-
ipants who were allocated to four treatments groups receiving a
different sunscreen formulation (spray, lotion and cream), four
times per day for 4 days, in indoor conditions, at a rate of
2 mg/cm2 on 75% of body surface area. All the four formula-
tions applied contained octocrylene at various concentrations:
2.35%, 6% or 10%. The overall maximum plasma concentra-
tions (Cmax) of octocrylene observed over the study duration,
ranged from 2.9 to 7.8 ng/mL. Furthermore, the AUC increased
from day 1 to day 4 of application and terminal half-life was rel-
atively long (mean range: 42–84 h), suggesting a possible accu-
mulation of octocrylene over time. However, given the
conditions of this study, further studies are needed to determine
the clinical significance of these findings. Although these data
have been published after our cut-off date (January 31, 2019),
we considered this study important to be included in our review
because this is the first one to assess the systemic availability of
octocrylene in humans.
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Conclusion Available in vitro dermal absorption studies of
octocrylene showed that most octocrylene concentrations are
found in the stratum corneum and that very few quantities are
found in the epidermis (0.4%) and in the receptor fluid
(<0.05%). In vivo, a very recent study in human volunteers
showed systemic exposure to octocrylene with maximal concen-
trations ranging from 2.9 to 7.8 ng/mL under indoor maximal
use conditions. Octocrylene has been found at very low amounts
in human milk, and some metabolites of octocrylene were pri-
marily detected in urine of volunteers using sunscreen products.
The clinical significance of systemic availability and the metabo-
lism of octocrylene in humans both need further investigation.
Repeated dose toxicity
Two repeated dose toxicity studies are available: one study was
carried out in rabbits via dermal route12 and the other was con-
ducted in rats via oral route (unpublished study as cited by
ECHA, 20195) (Table 1).
Topical route In the dermal 13-week repeated dose toxicity
study in rabbits (five animals per sex per dose), no significant
toxic effects were observed up to the maximum tested dose of
534 mg/kg bw/day.
Oral route
In the oral 13-week repeated dose toxicity study in rats (10 ani-
mals per sex per dose), rats were treated with octocrylene at
ingested doses of about 58, 175, 340 and 1085 mg/kg bw/day.
Effects on liver, thyroid and pituitary gland were observed in
animals receiving octocrylene at doses of 340 and 1085 mg/kg
bw/day. These changes were probably due to hepatic enzyme
induction reported with octocrylene in rats.
An additional study was conducted in rats to investigate
mechanisms related to potential thyroid effects of octocrylene
via enzyme induction in the liver. This study was divided into
two subsets with rats treated with octocrylene at doses of 63/72,
188/215 and 630/720 mg/kg bw/day in males/females, respec-
tively, via oral route for 14 or 28 days (Table 1). Effects on liver
and thyroid such as increased TSH serum levels (ranges of T3
and T4 levels were still physiological) were observed and these
were investigated. The conclusion states that octocrylene has the
potential to induce liver enzyme activity in rats at high doses
(340 and 1085 mg/kg bw/day) which in turn may induce indi-
rect effects on the thyroid.5 Indeed, the induction of hepatic
enzymes increased the clearance of thyroid hormones (T3 and
T4) and thus resulted in an increased TSH levels through a posi-
tive hormonal feedback mechanism. This mechanism of action,
i.e. impact on thyroid hormones by increasing the peripheral
metabolism of thyroid hormones through an induction of hep-
atic microsomal enzymes, is well described.13 In addition, rats
are far more sensitive to those thyroid effects than humans due
to the shorter plasma half-life of thyroxine (T4) and the
considerable differences in the transport proteins for thyroid
hormones compared to humans.5,14
Conclusion No systemic effects were reported after dermal
exposure to octocrylene in rabbits at very high dose (534 mg/
kg bw/day) compared with those used in cosmetic products.
After oral exposure, effects on liver and thyroid were reported in
a study conducted in rats at high doses (340 and 1085 mg/
kg bw/day in males). These effects were investigated in an addi-
tional mechanistic study which showed that effects on thyroid
were indirect and due to hepatic enzyme induction potential of
octocrylene in rats at very high oral doses.
Reproductive effects in animals
Overall, five studies assessing the reproductive effects of octocry-
lene in animals are available (Table 2). Two studies were con-
ducted via topical route12: a 13-week repeated dose toxicity
study in rabbits (see section Repeated dose toxicity) which
specifically investigated male genital organs and a developmental
toxicity study in rabbits. Three studies were carried out via oral
route: a developmental toxicity study in mice12 and two addi-
tional reproductive toxicity studies carried out in rats and
reported in summaries of safety data available on ECHA website
(unpublished studies as cited by the ECHA, 20195).
Topical route In the 13-week repeated dose toxicity, rabbits
(five animals per sex per dose) received topical applications of
octocrylene. No significant toxic effects were observed at doses
tested up to 534 mg/kg bw/day (see section Repeated dose toxic-
ity). Specific investigation on male genital organs was per-
formed, and no effects were reported on testicular and
epididymal morphology as well as on sperm count and motility.
In the developmental study conducted in rabbits (17 females
per dose), doses of octocrylene up to 267 mg/kg bw/day were
administered via dermal route. No effects on maternal, repro-
ductive and offspring parameters were reported.
Oral route
In the developmental study conducted in mice (12 females per
dose) treated orally with octocrylene at doses up 1000 mg/
kg bw/day, no effects on implantations, resorptions, number of
live, dead foetuses or bodyweight and pup size were observed.12
In the first developmental study available on ECHA’s web-
site,5 rats (25 females per dose) were treated with octocrylene via
oral route at doses of 100, 400 or 1000 mg/kg bw/day from day
6 to day 15 of gestation. Maternal effects were transient saliva-
tion at the highest dose and relative increased liver weights at the
middle and high dose compared with control. No effects were
observed in pups.
The second key study available on ECHA’s website is an
extended one-generation reproductive toxicity study carried out
in rats (P: 28 animals per sex per dose (28 males and 27 females);
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F1 generation: Cohort 1A: 19 animals per sex per dose/Cohort
1B: 25 animals per sex per dose/Cohort 2A: 10 animals per sex
per dose/Cohort 2B: 10 animals per sex per dose).5 No final con-
clusion is available, and it was not yet assessed by ECHA. In this
study, rats were treated with octocrylene at oral (diet) doses
(males/females, respectively) of 55/58, 153/163 and 534/550 mg/
kg bw/day. A decreased number of implantation sites and conse-
quently a lower number of pups delivered was observed in ani-
mals treated at the highest dose. No other effects on male and
female fertility and reproductive parameters such as oestrus
cycle, epididymal and testicular sperm parameters were observed
in all groups tested. Regarding pups, no effects on sexual and
neurodevelopmental were observed. Only low bodyweight was
observed in pups at the highest dose tested but this was consid-
ered due to relatively high compound intake via initiating food
uptake.
No data in humans are available.
Conclusion Based on available animal data, octocrylene does
not induce developmental or teratogenic effects. In an extended
one-generation reproductive toxicity study, only rats treated
with the highest dose of octocrylene via oral route showed a
decrease in the number of implantation sites and consequently a
low number of pups. This very high dose of 550 mg/kg bw/day
cannot be considered to be relevant to the dermal use of octocry-
lene as a cosmetic ingredient. Moreover, no other effects on male
and female fertility and reproductive parameters such as oestrus
cycle, epididymal and testicular sperm parameters were observed
in all groups tested. Regarding pups, no effects on sexual and
neurodevelopmental parameters were observed.
Endocrine disruption potential
According to commission regulation 2018/605 amending the
Plant Protection Regulation No. 1107/2009, a substance shall be
considered as having endocrine disrupting activity in humans if:
it shows an adverse effect in an intact organism or its progeny
leading to functional changes; it has an endocrine mode of
action (anti-oestrogenic, androgenic or anti-androgenic activity,
steroidogenesis alteration and thyroid and anti-thyroid hormone
activity); the adverse effect is a consequence of the endocrine
mode of action.
Several studies investigating the endocrine disruption poten-
tial are available since the assessment performed by the Danish
Centre on Endocrine Disrupters4 (Table 3). In a recent in vitro
study assessing the potential effects of chemical UV filters on
human sperm, no effects on sperm acrosome reaction, sperm
penetration, proportion of hyperactivated sperm cells or sperm
viability were observed.15
The following studies are available on the ECHA website (un-
published studies as cited by ECHA, 20195) in order to assess the
potential of endocrine activity of octocrylene. A uterotrophic
assay, which is a short-term screening test to evaluate the abilityT
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of a chemical to elicit biological activities consistent with ago-
nists or antagonists of natural oestrogens, was carried out in
immature female rats (10 per dose) treated with octocrylene at
doses of 250 and 1000 mg/kg bw/day via oral route. No effects
on uterine weights or uterine histopathology were observed.
Octocrylene has therefore no uterotrophic (oestrogenic) effects.
The second study was a Hershberger assay which is an in vivo
short-term screening test to evaluate the ability of a chemical to
elicit biological activities consistent with androgen agonists or
antagonists. Castrate-peripubertal male rats (six per dose)
received oral (gavage) octocrylene doses of 300 and 1000 mg/kg
bw/day. Decreases in absolute and relative ventral prostate and
muscle bulbocavernosus/levator ani weights were observed at the
highest dose but these results were not considered relevant and
can be explained by an enzyme induction. In addition, no octo-
crylene-related effects in clinical examinations, on hormone levels
(testosterone, dihydrotestosterone and luteinizing hormone) and
the histology of the prostate, seminal vesicle and the bulbo-ure-
thral gland were reported. Therefore, it was concluded that octo-
crylene showed neither androgen nor antiandrogen effects.
Conclusion
Octocrylene did not induce any adverse effects on human sperm
in vitro. In addition, in animal studies, neither oestrogenic nor
androgen/antiandrogen effects were reported. This was con-
firmed in an extended one-generation reproductive toxicity
study conducted in rats (see above, section Reproductive effects
in animals) that did not show any significant effects of octocry-
lene on female and male fertility and reproductive parameters.
Therefore, based on the current available data, mainly short-
term animal data, octocrylene does not show any endocrine dis-
ruption potential regarding reproductive and developmental
parameters.
Cutaneous effects
Skin irritation
Undiluted octocrylene did not induce dermal or eye irritation in
animal studies conducted in rabbits.5 In humans, irritant reac-
tions with octocrylene are rare15: in a multicentre study con-
ducted in 30 centres across 12 European countries, only seven
irritant reactions were observed in six of 1031 patients (0.6%)
patch-tested using 10% octocrylene in petrolatum for suspected
photoallergic contact dermatitis.16
Sensitization and photosensitization
In a sensitization animal study conducted in Guinea pigs, no
sensitization reactions following skin exposure to octocrylene
was observed.5
In humans, two main types of sensitization reactions are
reported in the scientific literature: contact allergy and photo-
contact allergy/photoallergy (after UV radiation).T
ab
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Regarding contact allergy attributed to octocrylene, some case
reports and positive patch test studies in both adults and chil-
dren can be found in the scientific literature.16–22
In particular, a recent study conducted in Germany showed
that among 2577 patients who were patch-tested with octocry-
lene at 10% in petrolatum, only two weak positive reactions were
reported – i.e. 0.08%.22 The authors concluded that contact
allergy attributed to octocrylene was ‘exceedingly rare’ although
it is used in many cosmetic products (in Germany, from 2006 to
2009, about 60% of 462 cosmetic products contained octocry-
lene).22 The same conclusion has been made in a European mul-
ticentre photopatch test study where contact allergy attributed
to octocrylene was reported in only 0.7% of 1031 patients patch-
tested with 10% octocrylene in petrolatum for suspected pho-
toallergic contact dermatitis.16 As shown in a study including
both adult and paediatric patients patch-tested because of
adverse skin reactions from sunscreen products, contact allergy
to octocrylene appears to be more frequent and severe in chil-
dren than in adults,23 probably because of the immaturity of the
skin epidermal barrier and the prevalence of atopic dermatitis in
young children.24 Based on these data, it can be concluded that
contact allergy attributed to octocrylene is rare in the general
population although this UV filter is commonly used in cos-
metic products.
Scientific literature also includes several case reports, positive
photopatch test studies and reviews on photoallergic reactions
attributed to octocrylene.16,23–34
Contrary to contact allergy, photoallergic contact dermatitis
to octocrylene is much more frequent in adults than in children,
in whom very few cases have been reported.23 For instance, in
the European photopatch test cited above, photocontact allergy
to octocrylene was reported in 4% of 1031 adult patients patch-
tested for suspected photoallergic contact dermatitis.16 The
occurrence of photoallergy to octocrylene is strongly related to a
previous photoallergy to topical ketoprofen.27,34 As a matter of
fact, patients with photoallergic contact dermatitis caused by
sunscreens and positive photopatch tests to octocrylene are
mainly reported in France, Belgium, Italy and Spain,27 countries
in which topical ketoprofen is popular. This was confirmed in a
recent study conducted in Italy where concomitant photocontact
allergy to ketoprofen was reported in 61.5% of 156 patients.31
Many authors indicated that photocontact allergy cases reported
with octocrylene are due to co-reactivity – i.e. are the result in
the majority of cases to a previous photocontact allergy to keto-
profen.22,27,34 Although the mechanism for the co-reactivity of
octocrylene and ketoprofen is not yet elucidated, de Groot
et al.27 ventured several hypotheses: (i) the benzophenone moiety
in the chemical structure of ketoprofen may be responsible for
photoallergy attributed to ketoprofen. Although the benzophe-
none moiety is not part of the octocrylene structure, aminolysis
and hydrolysis of octocrylene in the skin may result in the forma-
tion of benzophenone which then can lead to cross-reactivity.
However, at present, it cannot be definitively stated whether or
not the reactions are attributable to cross-sensitization; (ii) some
people may be hyper-photosusceptible to substances that are non-
relevant allergens; (iii) co-reactivity – i.e. concomitant sensitiza-
tion or prior or subsequent de novo photosensitization – may be
involved in place of cross-reaction. The recent study of Romita
et al.31 showed a decreasing trend in photocontact allergy attribu-
ted to octocrylene from 2014 to 2017, which could not be
explained by a restricted use of topical ketoprofen at a European
level, as allergy to ketoprofen is still high in their study. Aerts
et al.25 hypothesized that the presence of sensitizing impurities in
some commercial batches of octocrylene could be the real aller-
gen. The authors also suggested that recent commercial patch
tests, more purified than before, might produce false negative
reactions and underestimate the prevalence of photoallergy
cases.25
Conclusion The sensitizing potential of octocrylene has been
extensively reviewed in the scientific literature and contact
allergy to octocrylene is very rare in the general population. Pho-
tocontact allergy cases to octocrylene have been reported but are
rare in the general population, and previous photosensitization
to topical ketoprofen is apparently a prerequisite. Topical keto-
profen use is now discouraged by dermatologists and photocon-
tact allergy cases to octocrylene hopefully will be less of a
problem in the future.
Overall conclusion
Based on the current available safety data, octocrylene used as a
UV filter in cosmetic products at a concentration of 10% can be
considered as safe. There was no evidence of any endocrine disrup-
tion potential from experimental studies which demonstrated no
adverse effects on reproductive (e.g. oestrus cycle, epididymal and
testicular sperm parameters) and developmental parameters.
Effects on thyroid reported in repeated toxicity studies conducted
in rats at very high doses are species-specific and not relevant con-
sidering the doses at which octocrylene is used in human. The fre-
quency of contact allergy and photocontact allergy in non-
sensitized subjects is very rare with regards to its wide use in cos-
metic products, particularly in sunscreen products.
However, it should be pointed out that most data dealing with
the safety of octocrylene – except for cutaneous effects – are
in vitro or animal data. The clinical significance of systemic
availability and the metabolism of octocrylene in humans also
need further investigation.
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